Date: 2014-09-10
Type of information: Nomination
Compound:
Company: Novimmune (Switzerland)
Therapeutic area: Cancer - Oncology - Immunological diseases - Inflammatory diseases
Type agreement:
Action mechanism:
Disease:
Details: * On September 10, 2014, Novimmune announced that it has appointed Adrian Mills as the Company\'s Chief Business Officer and member of the Executive Committee, with immediate effect. Adrian will be leading Novimmune’s commercial development activities as well as Business Development. David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the Company. Adrian Mills is a British citizen joining Novimmune from GlaxoSmithKline plc (GSK), where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Adrian was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Adrian worked in management consulting and investment banking in the life sciences sector. He holds an MBA from the London Business School and an MA (Hons) Engineering from Queens’ College, Cambridge.
Financial terms:
Latest news:
